Ad-hoc News


  • Preliminary results show superior safety profile
  • Patients’ responses exceed expectations
  • Study will be amended with additional dose group
  • Clinical trial phase 2 to start this year
Patients’ responses to the...


  • Placement volume of EUR 2.8 million
  • Proceeds to be used specifically for further development of drugs
The Executive Board of MOLOGEN AG finalized a capital increase for contributions in cash with the exclusion of the...


The Berlin-based biotechnology company MOLOGEN AG, as part of an international research consortium, will receive funding from the European Commission within the 7th European Research Framework Programme. The total funding for the project amounts to...


  • Earnings influenced by extensive R&D expenses
  • Recruiting for clinical study with MGN1703 successfully started


The Berlin-based biotechnology company MOLOGEN AG has announced today the first patient enrolment in the phase I clinical study with MGN1703, an innovative cancer medicine. MGN1703 is based on the DNA immunomodulator dSLIM® developed by...


Berlin-based biotechnology company MOLOGEN has received approval from the relevant health authorities to carry out a study using its MGN1703 cancer drug, which is based on the dSLIM® DNA immunomodulator.


  • Key annual objectives for 2007 achieved
  • Key factor in earnings trend is planned investments in the product pipeline
  • Liquidity remain solid


Displaying results 1 bis 7 von 40

Page 1

Page 2

Page 3

Page 4

Page 5

Page 6



Share Subscription Facility with US investor GCF

Further Information

Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50